Cochrane · systematic review · CD003443
Perphenazine for schizophrenia
Hartung, B, Sampson, S, Leucht, S · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
7
No studies
7
Included studies
NR
No studies 7 · 50%Ungraded 0 · 0%Very low 7 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
PERPHENAZINE compared with PLACEBO for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Change over time ‐ no better or deterioration ‐ short term clinically defined PERPHENAZINE vs PLACEBO | RR 0.32 [0.13, 0.78] | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Mental state: Relapse ‐ short term clinical diagnosis PERPHENAZINE vs PLACEBO | RR 0.14 [0.02, 1.07] | 1 study · 48 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Adverse events: death ‐ not reported PERPHENAZINE vs PLACEBO | no estimate extracted | NR | No studies |
Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term PERPHENAZINE vs PLACEBO | RR 1 [0.07, 15.08] | 1 study · 48 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: serious adverse events ‐ not reported PERPHENAZINE vs PLACEBO | no estimate extracted | NR | No studies |
Economic outcomes ‐ not reported PERPHENAZINE vs PLACEBO | no estimate extracted | NR | No studies |
Service use and hospitalisation: admission ‐ not reported PERPHENAZINE vs PLACEBO | no estimate extracted | NR | No studies |
PERPHENAZINE compared with ANY ANTIPSYCHOTICS for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: Change over time ‐ no better or deterioration ‐ short and medium term as defined in each study PERPHENAZINE vs ANY ANTIPSYCHOTICS | RR 1.04 [0.91, 1.17] | 17 studies · 1879 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Mental state: State ‐ 'no effect' BPRS score reduction PERPHENAZINE vs ANY ANTIPSYCHOTICS | RR 1.24 [0.61, 2.52] | 4 studies · 383 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Death ‐ not reported PERPHENAZINE vs ANY ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
Adverse events: extrapyramidal adverse effects dystonia ‐ short term PERPHENAZINE vs ANY ANTIPSYCHOTICS | RR 1.36 [0.23, 8.16] | 4 studies · 416 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Other adverse events: any serious adverse event ‐ short and long term PERPHENAZINE vs ANY ANTIPSYCHOTICS | RR 0.98 [0.68, 1.41] | 2 studies · 1760 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Economic outcomes ‐ not reported PERPHENAZINE vs ANY ANTIPSYCHOTICS | no estimate extracted | NR | No studies |
Service use and hospitalisation: admission ‐ not reported PERPHENAZINE vs ANY ANTIPSYCHOTICS | no estimate extracted | NR | No studies |